Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,870 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sexually Transmitted Diseases, Viral Clear all

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 21 more

Conditions: HIV Disease
Interventions: alpha-1-Proteinase Inhibitor; Biological
Lead sponsor: Institute for Human Genetics and Biochemistry; Other
Eligibility: 30 Years to 70 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infection, HIV Infections
Interventions: Losartan, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: Counseling in the home; Behavioral
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years to 24 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Kaposi's Sarcoma, HIV Positive, AIDS
Interventions: 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: HIV Infection
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Medical Examination, Physical Examination, Proctoscopy with Biopsy, Questionnaire Administration; Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections, STI, HIV Pre-exposure Prophylaxis
Interventions: Combine mobile app, Motivational interview, HIV/STI testing; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 473 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Couples HIV testing and counseling, Individual HIV testing and counseling; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 17 Years to 65 Years · Male only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: HIV Infections
Interventions: SAV001-H; Biological
Lead sponsor: Sumagen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV/AIDS-associated Fatigue
Interventions: American ginseng, Placebo for American ginseng; Drug · Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, Cocaine Dependence
Interventions: ondansetron; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HIV Infections
Interventions: gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: HIV
Interventions: TMC125, Darunavir; Ritonavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV, Emphysema, HIV Infections
Interventions: Not listed
Lead sponsor: Philip Diaz; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Human Immunodeficiency Virus
Interventions: Dolutegravir/Lamivudine; Drug
Lead sponsor: Saint Michael's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Medication Adherence, HIV/AIDS
Interventions: Multilevel Gaming Adherence Intervention, Treatment as Usual +; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 15 Years to 34 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Jackson, Mississippi • Providence, Rhode Island

Conditions: HIV Infections
Interventions: Alendronate, Calcium carbonate, Vitamin D; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 25 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Progressive Multifocal Leukoencephalopathy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Camino Intervention; Behavioral
Lead sponsor: American University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Berkeley, California • Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections, Opioid Use, Trauma, Psychological
Interventions: Not listed
Lead sponsor: Alexis Roth; Other
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV/AIDS
Interventions: Infographic Intervention, Paper-based HIV self-testing information; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 322 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 3 more

Search by objective public record fields.

Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women

Therapy to Elevate CD4 Counts in HIV-1 Disease

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

Effects of Home Visits on Medication Adherence in Children and Youth With HIV

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men

Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial

Pharmacotherapy for HIV+ Stimulant Dependent Individuals

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Alveolar Macrophage Proteomics in HIV-associated Emphysema

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

A Mobile Gaming App to Improve Adherence to PrEP

The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients

Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)

A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP

El Camino HIV Prevention and Care Study

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

HIV Oral Testing Infographic Experiment

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease